{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:09:09Z","timestamp":1782860949965,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"crossref","award":["CMRPG8M0971"],"award-info":[{"award-number":["CMRPG8M0971"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"crossref","award":["CMRPG8M0971"],"award-info":[{"award-number":["CMRPG8M0971"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Taiwan Ministry of Health and Welfare Clinical Trial Center","award":["MOHW112-TDU-B-212-144004"],"award-info":[{"award-number":["MOHW112-TDU-B-212-144004"]}]},{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"crossref","award":["CMUHCH-CMU-113-002, DMR-113-079, and CMU112-S-04"],"award-info":[{"award-number":["CMUHCH-CMU-113-002, DMR-113-079, and CMU112-S-04"]}],"id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"DOI":"10.1186\/s12906-026-05400-8","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:46:38Z","timestamp":1778111198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between the subsequent benign prostate hyperplasia-related surgery risk and patients treated with Chinese herbal medicine: a population-based Taiwanese cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Ming-Yen","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Sin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Lun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Hsiu","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Ju","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuu-Jen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Hsiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"1","key":"5400_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12894-023-01397-1","volume":"24","author":"R Altman","year":"2024","unstructured":"Altman R, Ferreira R, Barragan C, Bhojani N, Lajkosz K, Zorn KC, Chughtai B, Annamalai G, Elterman DS. Comparing prostatic artery embolization to surgical and minimally invasive procedures for the treatment of benign prostatic hyperplasia: a systematic review and meta-analysis. BMC Urol. 2024;24(1):22.","journal-title":"BMC Urol"},{"issue":"1","key":"5400_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12894-023-01343-1","volume":"23","author":"YN Peng","year":"2023","unstructured":"Peng YN, Jin L, Peng EJ, Zhang L. Perioperative care based on roy adaptation model in elderly patients with benign prostatic hyperplasia: impact on psychological well-being, pain, and quality of life. BMC Urol. 2023;23(1):172.","journal-title":"BMC Urol"},{"issue":"3","key":"5400_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/JU.0000000000002785","volume":"208","author":"M Abou Zeinab","year":"2022","unstructured":"Abou Zeinab M, Kaouk J. The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management. Reply. J Urol. 2022;208(3):566.","journal-title":"J Urol"},{"issue":"2","key":"5400_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/JU.0000000000003077","volume":"209","author":"L Lenfant","year":"2023","unstructured":"Lenfant L, Pinar U, Roupret M, Mozer P, Chartier-Kastler E, Seisen T. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis. J Urol. 2023;209(2):314\u201324.","journal-title":"J Urol"},{"issue":"1","key":"5400_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12875-024-02378-5","volume":"25","author":"Z An","year":"2024","unstructured":"An Z, Zhou Q, Shao J, Xiao S, Zhao K, Wei W, Wu Y, Song Y, Yuan Q, Fu W, et al. Life disturbance and hospital visit experiences among Chinese patients with benign prostatic hyperplasia: a qualitative study. BMC Prim Care. 2024;25(1):149.","journal-title":"BMC Prim Care"},{"issue":"6","key":"5400_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.5152\/tud.2021.21262","volume":"47","author":"MA \u0130bis","year":"2021","unstructured":"\u0130bis MA, Cayan S, Tokatli Z, Orhan \u0130, Asc\u0131 R, Kocamanoglu F, Akbay E, Yaman O. Trends in benign prostatic hyperplasia surgery over the years: A multicenter 14-year retrospective study. Turk J Urol. 2021;47(6):501\u20138.","journal-title":"Turk J Urol"},{"issue":"6","key":"5400_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/1756287211426301","volume":"3","author":"B Rocco","year":"2011","unstructured":"Rocco B, Albo G, Ferreira RC, Spinelli M, Cozzi G, Dell\u2019orto P, Patel V, Rocco F. Recent advances in the surgical treatment of benign prostatic hyperplasia. Ther Adv Urol. 2011;3(6):263\u201372.","journal-title":"Ther Adv Urol"},{"issue":"4","key":"5400_CR8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/JU.0000000000002183","volume":"206","author":"LB Lerner","year":"2021","unstructured":"Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, Gandhi MC, Kaplan SA, Kohler TS, Martin L, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management. J Urol. 2021;206(4):806\u201317.","journal-title":"J Urol"},{"issue":"5","key":"5400_CR9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1476-5381.2011.01332.x","volume":"163","author":"S Ventura","year":"2011","unstructured":"Ventura S, Oliver V, White CW, Xie JH, Haynes JM, Exintaris B. Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). Br J Pharmacol. 2011;163(5):891\u2013907.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"5400_CR10","doi-asserted-by":"publisher","first-page":"17862","DOI":"10.1038\/s41598-019-54464-9","volume":"9","author":"JK Kim","year":"2019","unstructured":"Kim JK, Lee HJ, Hwang SI, Choe G, Kim HJ, Hong SK. The effect of 5 alpha-reductase inhibitor therapy on prostate cancer detection in the era of multi-parametric magnetic resonance imaging. Sci Rep. 2019;9(1):17862.","journal-title":"Sci Rep"},{"issue":"9","key":"5400_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.14740\/jocmr5255","volume":"16","author":"F Yang","year":"2024","unstructured":"Yang F, Hashim R, Philippou J. Tamsulosin and Dutasteride Combination Therapy for Asian Men With Moderate-to-Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review of Clinical Considerations That Influence the Prescription. J Clin Med Res. 2024;16(9):385\u201397.","journal-title":"J Clin Med Res"},{"issue":"1","key":"5400_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0022-5347(05)00041-8","volume":"175","author":"SA Kaplan","year":"2006","unstructured":"Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, Kusek JW, Nyberg LM Jr. Medical Therapy of Prostatic Symptoms Research G: Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25\u00a0ml or greater. J Urol. 2006;175(1):217\u201320. discussion 220\u2009\u2013\u2009211.","journal-title":"J Urol"},{"issue":"2","key":"5400_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.eururo.2008.10.037","volume":"55","author":"CG Roehrborn","year":"2009","unstructured":"Roehrborn CG, Siami P, Barkin J, Damiao R, Becher E, Minana B, Mirone V, Castro R, Wilson T, Montorsi F, et al. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol. 2009;55(2):461\u201371.","journal-title":"Eur Urol"},{"key":"5400_CR14","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3389\/fphar.2020.00658","volume":"11","author":"ZJ Yu","year":"2020","unstructured":"Yu ZJ, Yan HL, Xu FH, Chao HC, Deng LH, Xu XD, Huang JB, Zeng T. Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. Front Pharmacol. 2020;11:658.","journal-title":"Front Pharmacol"},{"issue":"1","key":"5400_CR15","doi-asserted-by":"publisher","first-page":"e0169248","DOI":"10.1371\/journal.pone.0169248","volume":"12","author":"HJ Kim","year":"2017","unstructured":"Kim HJ, Sun HY, Choi H, Park JY, Bae JH, Doo SW, Yang WJ, Song YS, Ko YM, Kim JH. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. PLoS ONE. 2017;12(1):e0169248.","journal-title":"PLoS ONE"},{"issue":"8","key":"5400_CR16","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/j.1464-410X.2005.05931.x","volume":"96","author":"K Dreikorn","year":"2005","unstructured":"Dreikorn K. Complementary and alternative medicine in urology. BJU Int. 2005;96(8):1177\u201384.","journal-title":"BJU Int"},{"key":"5400_CR17","doi-asserted-by":"publisher","first-page":"1358340","DOI":"10.3389\/fphar.2024.1358340","volume":"15","author":"H Zeng","year":"2024","unstructured":"Zeng H, Wang Z, Zhu W, Li X, Liu B, Chen C, Huang P, Luo Y. Comparative efficacy of commercial oral poly-herbal traditional Chinese medicine formulations combined with western medicine in benign prostatic hyperplasia management: a systematic review and network meta-analysis. Front Pharmacol. 2024;15:1358340.","journal-title":"Front Pharmacol"},{"issue":"4","key":"5400_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jtcme.2015.03.010","volume":"5","author":"H Yagi","year":"2015","unstructured":"Yagi H, Sato R, Nishio K, Arai G, Soh S, Okada H. Clinical efficacy and tolerability of two Japanese traditional herbal medicines, Hachimi-jio-gan and Gosha-jinki-gan, for lower urinary tract symptoms with cold sensitivity. J Tradit Complement Med. 2015;5(4):258\u201361.","journal-title":"J Tradit Complement Med"},{"key":"5400_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1472-6963-7-26","volume":"7","author":"FP Chen","year":"2007","unstructured":"Chen FP, Chen TJ, Kung YY, Chen YC, Chou LF, Chen FJ, Hwang SJ. Use frequency of traditional Chinese medicine in Taiwan. BMC Health Serv Res. 2007;7:26.","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"5400_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.eururo.2007.08.042","volume":"53","author":"JL Bosch","year":"2008","unstructured":"Bosch JL, Bangma CH, Groeneveld FP, Bohnen AM. The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. Eur Urol. 2008;53(4):819\u201325. discussion 825\u2009\u2013\u2009817.","journal-title":"Eur Urol"},{"issue":"4","key":"5400_CR21","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/JU.0000000000002184","volume":"206","author":"LB Lerner","year":"2021","unstructured":"Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, Gandhi MC, Kaplan SA, Kohler TS, Martin L, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART II-Surgical Evaluation and Treatment. J Urol. 2021;206(4):818\u201326.","journal-title":"J Urol"},{"issue":"27","key":"5400_CR22","doi-asserted-by":"publisher","first-page":"e4115","DOI":"10.1097\/MD.0000000000004115","volume":"95","author":"YH Yeh","year":"2016","unstructured":"Yeh YH, Chou YJ, Huang N, Pu C, Chou P. The trends of utilization in traditional Chinese medicine in Taiwan from 2000 to 2010: A population-based study. Med (Baltim). 2016;95(27):e4115.","journal-title":"Med (Baltim)"},{"issue":"7","key":"5400_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/iju.14853","volume":"29","author":"SC Ou","year":"2022","unstructured":"Ou SC, Huang ST, Lin MC, Chen WC, Huang CP, Lin HJ. Effects of Chinese herbal medicine in patients with benign prostatic hyperplasia: A nationwide cohort study in Taiwan. Int J Urol. 2022;29(7):623\u201330.","journal-title":"Int J Urol"},{"issue":"1","key":"5400_CR24","first-page":"e20961","volume":"14","author":"S Rojanasarot","year":"2022","unstructured":"Rojanasarot S, Cutone B, Bhattacharyya S, DeRouen K, Miller LE. Long-Term Risk of Surgery Following First Diagnosis of Benign Prostatic Hyperplasia in Middle-Aged Men. Cureus. 2022;14(1):e20961.","journal-title":"Cureus"},{"issue":"1","key":"5400_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","volume":"57","author":"CG Roehrborn","year":"2010","unstructured":"Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F, Comb ATSG. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123\u201331.","journal-title":"Eur Urol"},{"issue":"2","key":"5400_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/andr.12696","volume":"8","author":"YL Wang","year":"2020","unstructured":"Wang YL, Geng LG, He CB, Yuan SY. Chinese herbal medicine combined with tadalafil for erectile dysfunction: a systematic review and meta-analysis. Andrology. 2020;8(2):268\u201376.","journal-title":"Andrology"},{"issue":"4","key":"5400_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/aja.2012.173","volume":"15","author":"CH Ma","year":"2013","unstructured":"Ma CH, Lin WL, Lui SL, Cai XY, Wong VT, Ziea E, Zhang ZJ. Efficacy and safety of Chinese herbal medicine for benign prostatic hyperplasia: systematic review of randomized controlled trials. Asian J Androl. 2013;15(4):471\u201382.","journal-title":"Asian J Androl"},{"key":"5400_CR28","doi-asserted-by":"publisher","first-page":"1039622","DOI":"10.3389\/fphar.2023.1039622","volume":"14","author":"JY Park","year":"2023","unstructured":"Park JY, Park WY, Song G, Jung SJ, Kim B, Choi M, Kim SH, Park J, Kwak HJ, Ahn KS, et al. Panax ginseng C.A. meyer alleviates benign prostatic hyperplasia while preventing finasteride-induced side effects. Front Pharmacol. 2023;14:1039622.","journal-title":"Front Pharmacol"},{"issue":"2","key":"5400_CR29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/JU.0000000000001014","volume":"204","author":"H Zhang","year":"2020","unstructured":"Zhang H, Frendl DM, Wang Z, Olumi AF. High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia. J Urol. 2020;204(2):325\u201331.","journal-title":"J Urol"},{"issue":"3","key":"5400_CR30","first-page":"163","volume":"13","author":"CY Su","year":"2015","unstructured":"Su CY, Ming QL, Rahman K, Han T, Qin LP. Salvia miltiorrhiza: Traditional medicinal uses, chemistry, and pharmacology. Chin J Nat Med. 2015;13(3):163\u201382.","journal-title":"Chin J Nat Med"},{"issue":"2","key":"5400_CR31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/0929867053363397","volume":"12","author":"RW Jiang","year":"2005","unstructured":"Jiang RW, Lau KM, Hon PM, Mak TC, Woo KS, Fung KP. Chemistry and biological activities of caffeic acid derivatives from Salvia miltiorrhiza. Curr Med Chem. 2005;12(2):237\u201346.","journal-title":"Curr Med Chem"},{"issue":"6","key":"5400_CR32","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s11095-012-0670-3","volume":"29","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Won SH, Jiang C, Lee HJ, Jeong SJ, Lee EO, Zhang J, Ye M, Kim SH, Lu J. Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling. Pharm Res. 2012;29(6):1595\u2013608.","journal-title":"Pharm Res"},{"issue":"Suppl 11","key":"5400_CR33","first-page":"362","volume":"60","author":"H Fuse","year":"2002","unstructured":"Fuse H, Akashi T. [Chinese medicine for treatment of patients with prostatic hyperplasia]. Nihon Rinsho. 2002;60(Suppl 11):362\u20136.","journal-title":"Nihon Rinsho"},{"issue":"12","key":"5400_CR34","first-page":"857","volume":"53","author":"T Ogushi","year":"2007","unstructured":"Ogushi T, Takahashi S. Effect of Chinese herbal medicine on overactive bladder. Hinyokika Kiyo. 2007;53(12):857\u201362.","journal-title":"Hinyokika Kiyo"},{"issue":"2","key":"5400_CR35","doi-asserted-by":"publisher","first-page":"100484","DOI":"10.1016\/j.esxm.2021.100484","volume":"10","author":"T Kataoka","year":"2022","unstructured":"Kataoka T, Kawaki Y, Kito Y, Suzuki J, Mori T, Hotta Y, Sanagawa A, Kawade Y, Maeda Y, Furukawa-Hibi Y, et al. Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats. Sex Med. 2022;10(2):100484.","journal-title":"Sex Med"},{"issue":"6","key":"5400_CR36","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1089\/jmf.2018.0106","volume":"22","author":"M Leibbrand","year":"2019","unstructured":"Leibbrand M, Siefer S, Sch\u00f6n C, Perrinjaquet-Moccetti T, Kompek A, Csernich A, Bucar F, Kreuter MH. Effects of an Oil-Free Hydroethanolic Pumpkin Seed Extract on Symptom Frequency and Severity in Men with Benign Prostatic Hyperplasia : A Pilot Study in Humans. J Med Food. 2019;22(6):551\u20139.","journal-title":"J Med Food"},{"issue":"1","key":"5400_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.prnil.2023.01.002","volume":"11","author":"JVA Franco","year":"2023","unstructured":"Franco JVA, Tesolin P, Jung JH. Update on the management of benign prostatic hyperplasia and the role of minimally invasive procedures. Prostate Int. 2023;11(1):1\u20137.","journal-title":"Prostate Int"},{"issue":"1","key":"5400_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.37796\/2211-8039.1083","volume":"11","author":"A Sadeghimanesh","year":"2021","unstructured":"Sadeghimanesh A, Gholipour S, Torki A, Amini-Khoei H, Lorigooini Z, Habtemariam S. Inhibitory effects of Nigella sativa seed oil on the testosterone-induced benign prostatic hyperplasia in rats. Biomed (Taipei). 2021;11(1):19\u201325.","journal-title":"Biomed (Taipei)"},{"issue":"18","key":"5400_CR39","doi-asserted-by":"publisher","first-page":"e3493","DOI":"10.1097\/MD.0000000000003493","volume":"95","author":"X Dai","year":"2016","unstructured":"Dai X, Fang X, Ma Y, Xianyu J. Benign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta-Analysis of Observational Studies. Med (Baltim). 2016;95(18):e3493.","journal-title":"Med (Baltim)"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-026-05400-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-026-05400-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-026-05400-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:40:58Z","timestamp":1782859258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12906-026-05400-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5400"],"URL":"https:\/\/doi.org\/10.1186\/s12906-026-05400-8","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"19 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adheres to the Declaration of Helsinki and was conducted in accordance with the Institutional Review Board of the Research Ethics Committee of China Medical University Hospital [CMUH109-REC2-031(CR-3)], which waived the requirement for informed consent due to the retrospective design and the use of encrypted patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"219"}}